Lifeward names Ronen Tsimerman as Chief Financial Officer

Lifeward Ltd., incorporated in Israel, disclosed in an 8-K dated October 27, 2026 that its Board of Directors appointed Ronen Tsimerman, age 56, as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, effective November 1, 2026.¹

Tsimerman's most recent role was at Scopio Labs Ltd., where he served as chief financial officer from August through October 2026.¹ Before that, he served as chief financial officer of IceCure Medical Ltd (Nasdaq: ICCM) from May 2017 to August 2026 and as its chief operating officer from May 2018 to November 2025.¹ Earlier in his career, he served as chief financial officer of Insuline Medical Ltd. (TASE: INSL) from May 2015 to May 2017, as chief financial officer of Mer-Group Broadband division (TASE: CMER) from 2005 to 2013, and as vice president of finance of Mer-Group Telecom Division from 2013 to 2014.¹ He holds a bachelor's degree in business and MBA from the College of Management, in Israel.¹

Under the terms disclosed, Tsimerman's employment agreement, subject to shareholder approval of a renewed compensation policy at the annual general meeting scheduled for October 30, 2026, would provide a gross monthly base salary of NIS 70,000, an annual performance-based bonus with a target of not less than four monthly salaries, and a transaction bonus.¹ The agreement also includes a 3-month notice period for termination, increasing to four months for either party following any change in the Company's Chief Executive Officer, including the appointment of a permanent Chief Executive Officer.¹

The filing states that Tsimerman has no family relationship with any director or executive officer of the Company, and aside from his disclosed compensation arrangements, there are no other arrangements or related-party transactions requiring disclosure.¹